Condition Focus: Gout — NLRP3 Inflammasome Discovery

This is the paper that changed our understanding of gout. Published in Nature — the most prestigious scientific journal in the world — Martinon and colleagues at the University of Lausanne identified for the first time that monosodium urate (MSU) crystals, the causative agent of gout, activate a specific molecular complex called the NLRP3 inflammasome to produce the inflammatory cytokines IL-1β and IL-18.

Before this discovery, gout was understood as a crystal deposition disease, but the precise molecular switch that translated crystal presence into the explosive inflammatory response of a gout flare was unknown. Martinon showed that when immune cells (macrophages) encounter MSU crystals, they engulf them. This phagocytosis event triggers the assembly of the NLRP3 inflammasome — a multi-protein complex consisting of NLRP3, ASC adapter protein, and caspase-1 enzyme. Once assembled, caspase-1 cleaves pro-IL-1β and pro-IL-18 into their active forms, which are released from the cell and initiate the massive inflammatory cascade that patients experience as a gout flare.

The study also demonstrated that calcium pyrophosphate (CPPD) crystals activate the same pathway, explaining the similar inflammatory phenotype in pseudogout. NLRP3-deficient mice showed dramatically reduced inflammatory responses to crystal injection, confirming that NLRP3 is not just involved — it is essential.

This paper is in our library because understanding the disease mechanism is the prerequisite for understanding why photobiomodulation works against it. PBM suppresses the exact outputs of this pathway — IL-1β and IL-18 — as demonstrated in subsequent PBM studies included in this library.

G.O.A.T. for Gout Alignment:
The NLRP3 inflammasome pathway identified in this paper is what the G.O.A.T. is designed to counteract. PBM does not block NLRP3 directly, but it suppresses the downstream outputs (IL-1β, IL-18) and modulates the upstream triggers (mitochondrial ROS, NF-κB priming) through mitochondrial photon absorption and cellular signalling. Understanding this mechanism explains why PBM addresses gout inflammation rather than masking pain.

Link to original research here

Editor’s note: This landmark paper defines the disease target. For how PBM suppresses the NLRP3 outputs identified here, see Shamloo et al 2023, which demonstrated IL-1β and IL-18 reduction with dual-wavelength PBM. The TXNIP-ROS pathway that primes NLRP3 is detailed in Kim et al 2023. For the finding that even soluble urate activates NLRP3 before crystals form, see Braga et al 2017.

Related Articles

• PBM Suppresses NLRP3 Inflammasome Outputs with Dual Wavelength – Shamloo et al 2023
• Role of NLRP3 in Pathogenesis and Treatment of Gout Arthritis – Jin et al 2023
• The Role of the NLRP3 Inflammasome in Gout – Kingsbury et al 2011
• Soluble Uric Acid Activates the NLRP3 Inflammasome – Braga et al 2017
• Mechanism of NLRP3 Inflammasome Activation and Pathogenic Implication in Gout – Kim et al 2023

Key Takeaways

• Published in Nature: MSU crystals activate the NLRP3 inflammasome — the molecular trigger for gout flares
• NLRP3 activation produces IL-1β and IL-18, the primary drivers of gout inflammation
• NLRP3-deficient mice showed dramatically reduced crystal-induced inflammation
• Same pathway activated by CPPD crystals (pseudogout), explaining shared inflammatory phenotype
• PBM targets the outputs of this exact pathway — the foundation for photobiomodulation in gout

Study Overview

Full Citation

Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 440(7081), 237–241. View Publication